Hancock Jaffee Laboratories, a California-based healthcare technology company focused on cardiac and vascular conditions, has received the FDA’s breakthrough device designation for its VenoValve device for chronic venous insufficiency.
The company's first-in-human study, shared with the public in December 2020, found that VenoValve was associated with significant improvements in reflux, disease manifestations and pain following surgery. In addition, there were no material adverse events 30 days after implantation.
"device" - Google News
August 06, 2021 at 04:17AM
https://ift.tt/3Aekmeh
FDA grants breakthrough device designation to new chronic venous insufficiency device - Cardiovascular Business
"device" - Google News
https://ift.tt/2KSbrrl
https://ift.tt/2YsSbsy
Bagikan Berita Ini
0 Response to "FDA grants breakthrough device designation to new chronic venous insufficiency device - Cardiovascular Business"
Post a Comment